Showing 1–25 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Grace AG, Mittal A, Jain S, Tripathy JP, Satyanarayana S, et al.
…eople do not complete this full course. Shortened treatment regimens that are equally effective and safe could improve treatment success. Objectives To evaluate the efficacy and safety of shortened treatment regimens versus the standard six-month treatment regimen for individuals…
Hissar S, Velayutham B, Tamizhselvan M, Rathinam S, Arunbabu C, et al.
Background Tuberculosis (TB) lymphadenitis is the most common form of extra-pulmonary TB, and the treatment duration is six months. This non-inferiority based randomized clinical trial in South India evaluated the efficacy and safety of a four-month ofloxacin containing regimen i…
Abangah G, Raughani A, Asadollahi P, Asadollahi K
Aim This study compares the effects of two drug regimens for Helicobacter pylori ( H. pylori ) infection resistant to the first line drug regimen among patients referred to Ilam clinics, Iran. Background Single drug regimen is not effective for H. pylori infection and therefore, …
Ghosh R, Roy S, Rashid MK
Purpose The Revised National Tuberculosis Control Programme (RNTCP) is now introducing daily fixed-dose regimen instead of Directly Observed Treatment, Short Course (DOTS) regimen for treatment of drug-sensitive tuberculosis (TB) in India. It would be beneficial to understand the…
Ji L, Yang W, Gao LJ, Zhang BY, Xu YQ, et al.
…ts often cannot tolerate traditional intensive chemotherapy regimens, and finding the optimal timing in the treatment of both AML and active pulmonary TB is complex. Neglecting timely treatment can lead to serious complications and even fatal outcomes. The present paper reports t…
Sacks HS
Source citation Paton NI, Cousins C, Suresh C, et al; TRUNCATE-TB Trial Team. Treatment strategy for rifampin-susceptible tuberculosis. N Engl J Med. 2023;388:873-887. 36808186.
Ryckman TS, McQuaid CF, Cohen T, Menzies NA, Kendall EA
…of separate rifampicin-susceptible and rifampicin-resistant regimens. We estimated incremental cures; averted deaths, secondary cases, and costs; and prices below which a pan-tuberculosis regimen would be cost saving. We also assessed scenarios intended to describe which mechanis…
Sisay M, Edessa D, Ayele Y, Getachew M
…pattern of and reasons for change of antiretroviral therapy regimens among HIV/AIDS patients at Jugel Hospital, Eastern Ethiopia. Methods A retrospective cross-sectional study was conducted to review medical records of 220 patients who had been on treatment and experienced regime…
Azmeraw M, Workineh Y, Girma F, Kassaw A, Kerebeh G, et al.
…rtant to maintain children's initial antiretroviral therapy regimens. However, the incidence and predictive factors of initial antiretroviral therapy regimen changes in the research context are still unknown in the study setting. So, the study was aimed to assess incidence and pr…
Stagg HR, Thompson JA, Lipman MCI, Sloan DJ, Flook M, et al.
… nonadherence occurs on the forgiveness of antituberculosis regimens. Methods: Using data from three randomized controlled trials comparing experimental 4-month regimens for drug-sensitive tuberculosis with the standard 6-month regimen, we used generalized linear models to examin…
Velayutham B, Jawahar MS, Nair D, Navaneethapandian P, Ponnuraja C, et al.
…iority. We tested the efficacy and safety of 3- and 4-month regimens containing moxifloxacin in a randomised clinical trial in pulmonary TB (PTB) patients in South India. Methods New, sputum-positive, adult, HIV-negative, non-diabetic PTB patients were randomised to 3- or 4-month…
Vesga JF, Lienhardt C, Nsengiyumva P, Campbell JR, Oxlade O, et al.
…en important improvements in available preventive treatment regimens for tuberculosis (TB), and research is ongoing to develop these further. To assist with the formulation of target product profiles for future regimens, we examined which regimen properties would be most influent…
Nicholas I Paton, Christopher Cousins, Intan P Sari, Erlina Burhan, Nan-Kai Ng, et al.
…D:** WHO recommends a 2-month optimal duration for new drug regimens for rifampicin-susceptible tuberculosis. We aimed to investigate the efficacy and safety of the 8-week regimens that were assessed as part of the TRUNCATE management strategy of the TRUNCATE-TB trial. **METHODS…
Liu Y, Pertinez H, Davies GR, Gillespie SH, Coates AR, et al.
…oxifloxacin for isoniazid or ethambutol in standard anti-TB regimens reduces the treatment duration and relapse rates in animal studies, and 4-month regimens were not noninferior in clinical trials. Resuscitation-promoting factor (RPF)-dependent bacilli have recently been implica…
Shabadi N, Prashanth Kumar NK, Prakash B, Kulkarni P, Narayana Murthy MR
Introduction In the context of changing over from an intermittent treatment regimen to a daily regimen, it becomes crucial to understand the impact of a daily regimen on the treatment process and outcome. It enables health professionals to strengthen strategies, to enhance the qu…
Musisi E, Wyness A, Eldirdiri S, Dombay E, Mtafya B, et al.
…andard-of-care and experimental anti-tuberculosis treatment regimens on the respiratory microbiome and implications for treatment outcomes. Methods In this retrospective study, we analysed the sputum microbiome of participants with tuberculosis treated with six experimental regim…
Kort F, Fournier Le Ray L, Chauffour A, Jarlier V, Lounis N, et al.
…nds supervising the treatment of tuberculosis. Intermittent regimens have the potential to simplify the supervision and improve compliance. Our objective was to analyse the sterilising activity of once-weekly regimens based on drugs with a long half-life, bedaquiline and rifapent…
Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, et al.
…s (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Markov model to estimat…
Ge Q, Ma Y, Zhang L, Ma L, Zhao C, et al.
…ate, adverse reaction rate, and recurrence rate between two regimens. Multivariate Cox regression model was used to identify the potential risk factors for recurrence after successful treatment with proportional hazards assumptions tested for all variables. Results A total of 381…
Xiaonan Geng, Fan Zhang, Ruichao Liu, Fuzhen Zhang, Ziwen Li, et al.
… and compare the effectiveness of different DR-TB treatment regimens and to assess their safety profiles based on the frequency of adverse events and drug-specific reactions. **METHODS:** We systematically searched PubMed, Web of Science, and Embase for relevant studies publishe…
Muniyandi M, Karikalan N, Velayutham B, Rajsekar K, Padmapriyadarsini C
Globally efforts are underway to shorten the existing 6-month tuberculosis (TB) treatment regimen for drug-sensitive patients, which would be equally effective and safe. At present, there is a lack of evidence on the cost implications of a shorter 4-month TB regimen in India. Thi…
Fekadu G, Wang Y, You JHS
BACKGROUND: Recent clinical findings reported improvement in the treatment outcomes of highly resistant TB (HDR-TB) with the pretomanid (Pa) based regimen. This study aimed to evaluate the cost-effectiveness of the Pa-based regimen for HDR-TB treatment from the perspective of the…
Jindani A, Atwine D, Grint D, Bah B, Adams J, et al.
BACKGROUND: Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid and secure lung sterilization and may enable shorter tuberculosis treatment regimens. METHODS: We …
Tasneen R, Garcia A, Converse PJ, Zimmerman MD, Dartois V, et al.
…rine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen. In BALB/c mice, replacing rifapentine in the PZM backbone with bedaquilin…
Berg A, Clary J, Hanna D, Nuermberger E, Lenaerts A, et al.
…necessitating the development of new and improved treatment regimens. Nonclinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in the …